Deerfield Management Company, L.P. (Series C) Cogent Biosciences, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $3.95 Billion
- Q1 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 2,633,862 shares of COGT stock, worth $16.1 Million. This represents 0.4% of its overall portfolio holdings.
Number of Shares
2,633,862
Previous 2,631,000
0.11%
Holding current value
$16.1 Million
Previous $20.5 Million
23.12%
% of portfolio
0.4%
Previous 0.51%
Shares
10 transactions
Others Institutions Holding COGT
# of Institutions
196Shares Held
116MCall Options Held
61.9KPut Options Held
223K-
Kynam Capital Management, LP Princeton, NJ9.11MShares$55.6 Million4.6% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY8.96MShares$54.8 Million2.75% of portfolio
-
Commodore Capital LP New York, NY8.89MShares$54.3 Million5.22% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$44.5 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$42.6 Million10.05% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $402M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...